Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Treatment of a single migraine attack with 200 mg lasmiditan demonstrated a strong association between achieving freedom from pain and central nervous system common treatment-emergent adverse events (CTEAE).

Major finding: Significantly higher proportion of patients treated with 200 mg lasmiditan who were pain-free vs those who experienced moderate-to-severe pain at 2 hours post-dose reported ≥1 CTEAE (48.2% vs 28.7%; P < .001). A significantly higher proportion of patients reporting ≥1 vs 0 CTEAE were pain-free at 2 hours (39.0% vs 30.2%; P < .001). However, the absence of CTAE did not translate to the lack of efficacy.

Study details: This was a post hoc analysis of 4 randomized phase 2/3 trials including 6602 patients with migraine with or without aura who received lasmiditan (50, 100, or 200 mg) or placebo.

Disclosures: This study was funded by Eli Lilly and Company. Six authors reported being employees and minor stockholders of Eli Lilly. RB Lipton reported ties with Eli Lilly and other sources and owning stock or stock options in 3 companies.

Source: Doty EG et al. The association between the occurrence of common treatment-emergent adverse events and efficacy outcomes after lasmiditan treatment of a single migraine attack: Secondary analyses from four pooled randomized clinical trials. CNS Drugs. 2022;36:771–783 (Jul 2). Doi: 10.1007/s40263-022-00928-y

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Long-term treatment with galcanezumab led to three-quarters of patients with chronic migraine (CM) reverting to episodic migraine (EM), with more than half persistently reverting to episodic migraine (EM) under real-life conditions.

Major finding: Over 1 year, approximately ≥75% of patients reverted from CM to EM at each visit, with persistent reversion from CM to EM and medium-to-low frequency EM being reported by 52.3% and 20.6% of patients, respectively. Older age at onset (P  =  .01) and less frequent baseline monthly migraine days (P  =  .005) significantly increased the reversion frequency to EM.

Study details: Findings are from a 12-month observational, longitudinal cohort study, GARLIT, including 155 patients with CM who received galcanezumab.

Disclosures: This study did not receive any specific funding. Several authors reported receiving grants or honoraria from various sources.

Source: Altamura C et al for the GARLIT Study Group. Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: The 12-month observational, longitudinal, cohort multicenter GARLIT experience. J Neurol. 2022 (Jun 28). Doi: 10.1007/s00415-022-11226-4

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: Eptinezumab (100 and 300 mg) was efficacious compared with placebo with an acceptable safety and tolerability profile in patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments.

Major finding: In 1-12 weeks, 100 and 300 mg eptinezumab vs placebo led to a significantly higher reduction in mean monthly migraine days (difference from placebo −2.7 and −3.2, respectively; both P < .0001) and higher odds of ≥75% migraine responder rates (odds ratio 9.2 and 11.4, respectively; both P < .0001), with comparable treatment-emergent adverse events.

Study details: Findings are from the phase 3b DELIVER trial including 892 patients with episodic and chronic migraine and 2-4 previous unsuccessful preventive treatments who were randomly assigned to receive eptinezumab (100 or 300 mg) or placebo.

Disclosures: This study was supported by H Lundbeck. Five authors reported being full-time employees or owning stock or stock options in H Lundbeck or its subsidiaries. Several authors reported ties with various sources and scientific journals.

Source: Ashina M et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597-607 (Jul 1). Doi: 10.1016/S1474-4422(22)00185-5

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: A prospective cohort study found the cumulative incidence of myocarditis among patients treated with immune checkpoint inhibitors (ICI) to be 3%.

Major finding: Three cases (2 definite and 1 possible) of myocarditis were reported over a follow-up of 6 months, with all cases being mild and without major adverse cardiac events. The mean time to onset of myocarditis was 144 ± 3 days.

Study details: The data come from a real-world prospective cohort study involving 99 patients with lung cancer treated with ICI at a French university hospital.

Disclosures: No funding information was available. The authors reported no conflicts of interest.

Source: Faubry C et al. A prospective study to detect immune checkpoint inhibitors associated with myocarditis among patients treated for lung cancer. Front Cardiovasc Med. 2022;9:878211 (Jun 6). Doi: 10.3389/fcvm.2022.878211

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Airflow limitation is linked to an increased risk for lung cancer, with the association being pronounced in ever smokers.

Major finding: Airflow limitation vs no limitation was associated with a higher risk for lung cancer (adjusted hazard ratio [aHR] 1.7; 95% CI 1.4-2.3). The association was greater among current smokers (HR 2.2; 95% CI 1.5-3.2) and former smokers (HR 2.1; 95% CI 1.4-3.2) compared with never smokers (HR 0.9; 95% CI 0.4-2.1).

Study details: The data come from a prospective population-based cohort study involving 98,630 participants.

Disclosures: No funding information was available. HJM Groen, R Vliegenthart, and W Timens declared receiving personal fees from pharmaceutical companies outside this work. The other authors reported no disclosures.

Source: Du Y et al. Airflow limitation increases lung cancer risk in smokers: The Lifelines Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31(7):1442–1449  (May 9). Doi: 10.1158/1055-9965.EPI-21-1365

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Adjuvant postoperative chemotherapy improved relapse-free survival (RFS) and overall survival (OS) in patients with early-stage resected non–small-cell lung cancer (NSCLC), with the cisplatin-vinorelbine regimen being the most effective therapeutic method with tolerable toxicity.

Major finding: Compared with the observation (control) group, the chemotherapy group showed a significant RFS (hazard ratio [HR] 0.67; P < .0001) and OS (HR 0.80; P < .0001) advantage, with the benefits being most prominent with the cisplatin-vinorelbine regimen (RFS: HR 0.63; 95% CI 0.43-0.87; and OS: HR 0.74; 95% CI 0.63-0.87). Hematological toxicities and nausea or vomiting were not higher with cisplatin-vinorelbine vs other chemotherapy regimens.

Study details: The data come from a systematic review with network meta-analysis of 20 randomized controlled trials including 5483 participants.

Disclosures: This study was funded by the Chinese National Natural Science Foundation Project. The authors declared no conflicts of interest.

Source: Pang LL et al. Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: A Bayesian network meta-analysis. BMJ Open. 2022;12:e057098 (Jun 13). Doi: 10.1136/bmjopen-2021-057098

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206

Key clinical point: Androgen deprivation therapy (ADT) for previously diagnosed prostate cancer may improve survival in patients subsequently diagnosed with lung cancer.

Major finding: Patients who received vs did not receive ADT for previously diagnosed prostate cancer showed improved survival after lung cancer diagnosis (adjusted hazard ratio of death 0.88; P  =  .022) and a shorter latency period to the diagnosis of lung cancer (40 vs 47 months; P < .001).

Study details: This study evaluated 367,750 patients with lung cancer, of which 11,061 patients had an initial prostate cancer diagnosis and subsequent lung cancer diagnosis, 3017 had an initial lung cancer diagnosis and subsequent prostate cancer diagnosis, and the remaining patients had isolated lung cancer diagnosis.

Disclosures: This study received no external funding. B Nazha and TK Owonikoko reported receiving advisory or consulting fees from various sources.

Source: Nazha B et al. Concurrent androgen deprivation therapy for prostate cancer improves survival for synchronous or metachronous non-small cell lung cancer: A SEER–Medicare database analysis. Cancers (Basel). 2022; 14(13);3206 (Jun 30). Doi: 10.3390/cancers14133206

Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) increases the risk for distant organ metastasis in patients with non—small-cell lung cancer (NSCLC) receiving chemotherapy, with the risk being much higher in patients without vs with chemotherapy-induced myelosuppression.

Major finding: Use vs non-use of rhG-CSF more than doubled the risk for distant organ metastasis (48.37% vs 26.23%; adjusted hazard ratio [HR] 2.33; P < .01), with the risk being much higher in patients presenting without vs with myelosuppression (HR 3.34; 95% CI 1.86-6.02 vs HR 0.71; 95% CI 0.17-2.94; P_interaction < .01).

Study details: Findings are from a retrospective cohort study including 307 patients with NSCLC who underwent surgery and postoperative systemic chemotherapy, of which 246 patients received rhG-CSF treatment during chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Wang Y et al. rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy. BMC Cancer. 2022;22:741 (Jul 7). Doi:  10.1186/s12885-022-09850-4

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The concomitant use of gastric acid suppressants (GAS) may be associated with poor survival outcomes in patients with non—small-cell lung cancer (NSCLC) receiving programmed death-1/ligand-1 (PD-1/PD-L1) inhibitors.

Major finding: Use of PD-1/PD-L1 inhibitors with vs without GAS worsened progression-free survival by 32% (hazard ratio [HR] 1.32; P < .001) and overall survival by 36% (HR 1.36; P < .001).

Study details: The data come from a meta-analysis of 10 retrospective studies and 1 prospective cohort study including 5892 patients with NSCLC who were receiving PD-1/PD-L1 inhibitors.

Disclosures: This study was supported by Anhui University Natural Science Research Project, China. The authors declared no conflicts of interest.

Source: Wang M et al. Influence of concomitant gastric acid suppressants use on the survival of patients with non-small cell lung cancer treated with programmed death-1/ligand-1 inhibitors: A meta-analysis. Int Immunopharmacol. 2022;110:108955 (Jun 21). Doi:  10.1016/j.intimp.2022.108955

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538

Key clinical point: The addition of postoperative radiotherapy (PORT) to surgery and adjuvant chemotherapy prolonged overall survival by 39% and cancer-specific survival by 53% in patients with early small cell lung cancer (SCLC).

Major finding: PORT vs no PORT was associated with a significantly extended median overall survival (8.58 vs 5.17 years; hazard ratio [HR] 0.61; P  =  .032) and cancer-specific survival (11.33 vs 8.08 years; HR 0.47; P  =  .0086).

Study details: The data come from a population-based retrospective cohort study involving 278 patients with stage I-IIA SCLC who underwent surgery and received adjuvant chemotherapy.

Disclosures: This study was funded by the National Natural Science Foundation of China and others. The authors declared no conflicts of interest.

Source: Li J et al. Additional postoperative radiotherapy prolonged the survival of patients with i-iia small cell lung cancer: Analysis of the SEER database. J Oncol. 2022;6280538 (Jun 18). Doi: 10.1155/2022/6280538